دورية أكاديمية
أعرض في EDS

The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review.

التفاصيل البيبلوغرافية
العنوان: The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review.
المؤلفون: Abu Serhan H; Department of Ophthalmology, Hamad Medical Corporations, Al Sadd, Al Rayyan St., PO: 3050, Doha, Qatar. HAbuserhan@hamad.qa., Abu Suilik H; Faculty of Medicine, Hashemite University, Zarqa, Jordan., Hassan AK; Gavin Herbert Eye Institute, University of California, Irvine, CA, USA., AlSamhori JF; School of Medicine, University of Jordan, Amman, Jordan., Hassan AR; Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, MI, USA., Siddiq A; Faculty of Pharmacy, Mansoura University, Mansoura, Egypt., Ahmed N; Department of Ophthalmology, Hamad Medical Corporations, Al Sadd, Al Rayyan St., PO: 3050, Doha, Qatar., Elnahry AG; Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA.; Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt.
المصدر: International ophthalmology [Int Ophthalmol] 2024 Apr 23; Vol. 44 (1), pp. 189. Date of Electronic Publication: 2024 Apr 23.
نوع المنشور: Systematic Review; Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Kluwer Country of Publication: Netherlands NLM ID: 7904294 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-2630 (Electronic) Linking ISSN: 01655701 NLM ISO Abbreviation: Int Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer
Original Publication: The Hague, Junk.
مواضيع طبية MeSH: COVID-19 Vaccines*/adverse effects , White Dot Syndromes*/diagnosis, Humans ; COVID-19/prevention & control ; COVID-19/epidemiology ; SARS-CoV-2/immunology ; Tomography, Optical Coherence/methods
مستخلص: Purpose: To review all studies reporting the onset of white dot syndromes following COVID-19 vaccines.
Methods: Our protocol was registered prospectively on PROSPERO [registration number: CRD42023426012]. We searched five different databases including PubMed, Scopus, Web of Science, Google Scholar, and Science Direct up to May 2023. All the studies that reported the occurrence of white dot syndrome following COVID-19 vaccines were included. All statistical tests were conducted with a 95% confidence interval and a 5% error margin. A p value of less than 0.05 was considered statistically significant. The methodological quality of included studies was performed using the IHE Quality Appraisal Checklist for Case Series studies and JBI Critical Appraisal Checklist for Case Reports.
Results: Fifty studies involving seventy-one subjects were included. Multiple evanescent white dot syndrome (MEWDS) was the most common disease (n = 25, 35.2% %), followed by acute macular neuroretinopathy (AMN) (n = 22, 31.0%) and acute posterior multifocal placoid pigment epitheliopathy (APMPPE) (n = 4, 5.6%). They were mostly unilateral (n = 50, 70.4%). The presenting symptoms were blurred vision (n = 26, 36.6%), paracentral scotoma (n = 19, 26.8%), visual field disturbance, and photopsia (n = 7, 9.9%). The mean duration for follow-up was 10.15 ± 14.04 weeks. Nineteen subjects (29.69%) received steroids with improvement reported in 68.4%. Eleven subjects (17.19%) were managed by observation only with reported full recovery and improvement.
Conclusion: White dot syndromes are very rare entities. Our findings highlight a possible association between COVID-19 vaccines and the occurrence of white dot syndromes. However, larger studies with good quality should be implemented to confirm these findings.
(© 2024. The Author(s).)
References: J Ophthalmic Vis Res. 2017 Apr-Jun;12(2):132-134. (PMID: 28540002)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Vaccines (Basel). 2022 Feb 21;10(2):. (PMID: 35214800)
Can J Ophthalmol. 2023 Jun;58(3):e122-e124. (PMID: 36288774)
Autoimmun Rev. 2014 Dec;13(12):1174-81. (PMID: 25151974)
Ocul Immunol Inflamm. 2011 Dec;19(6):426-30. (PMID: 22106911)
Medicine (Baltimore). 2022 Jan 14;101(2):e28582. (PMID: 35029236)
Vaccines (Basel). 2022 Oct 22;10(11):. (PMID: 36366285)
J Clin Med. 2021 Dec 19;10(24):. (PMID: 34945256)
Am J Ophthalmol Case Rep. 2022 Mar;25:101281. (PMID: 35075438)
JAMA Ophthalmol. 2021 Jul 1;139(7):e212471. (PMID: 34287612)
Ocul Immunol Inflamm. 2023 Aug;31(6):1279-1282. (PMID: 36780589)
Ocul Immunol Inflamm. 2021 May 19;29(4):753-757. (PMID: 34344280)
Case Rep Ophthalmol. 2022 Feb 14;13(1):96-103. (PMID: 35350236)
Cureus. 2022 Jul 31;14(7):e27502. (PMID: 36060339)
Am J Ophthalmol Case Rep. 2022 Sep;27:101592. (PMID: 35642221)
JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899)
Can J Ophthalmol. 2019 Aug;54(4):e199-e203. (PMID: 31358170)
Retin Cases Brief Rep. 2022 Jan 1;16(1):5-8. (PMID: 34608019)
Ocul Immunol Inflamm. 2023 Jan;31(1):220-223. (PMID: 34851236)
Retin Cases Brief Rep. 2022 Jan 1;16(1):9-11. (PMID: 34608018)
J Fr Ophtalmol. 2022 Sep;45(7):e299-e302. (PMID: 35717218)
Ocul Immunol Inflamm. 2022 Jul;30(5):1234-1239. (PMID: 35050829)
Nat Rev Immunol. 2021 Oct;21(10):626-636. (PMID: 34373623)
Am J Ophthalmol Case Rep. 2021 Dec;24:101207. (PMID: 34580648)
BMC Ophthalmol. 2023 May 24;23(1):233. (PMID: 37226110)
Indian J Ophthalmol. 2021 Dec;69(12):3398-3420. (PMID: 34826968)
J Fr Ophtalmol. 2022 Sep;45(7):e306-e308. (PMID: 35643738)
Arq Bras Oftalmol. 2022 Jan 21;85(2):186-189. (PMID: 35298582)
Vaccines (Basel). 2022 Nov 07;10(11):. (PMID: 36366386)
Jpn J Ophthalmol. 2023 Jan;67(1):14-21. (PMID: 36417027)
Vaccines (Basel). 2022 Dec 28;11(1):. (PMID: 36679914)
Turk J Ophthalmol. 2023 Jun 21;53(3):186-191. (PMID: 37345327)
J Curr Ophthalmol. 2022 Nov 30;34(3):373-378. (PMID: 36644462)
Int Ophthalmol Clin. 2015 Summer;55(3):111-31. (PMID: 26035764)
Case Rep Ophthalmol. 2014 Feb 01;5(1):38-43. (PMID: 24707270)
J Ophthalmic Vis Res. 2021 Jul 29;16(3):490-501. (PMID: 34394876)
Am J Ophthalmol Case Rep. 2022 Apr 20;26:101538. (PMID: 35514800)
Optom Vis Sci. 2022 Jun 1;99(6):534-539. (PMID: 35412479)
Ocul Immunol Inflamm. 2022 Jul;30(5):1278-1281. (PMID: 35442848)
Ocul Immunol Inflamm. 2023 Aug;31(6):1299-1304. (PMID: 37043615)
Ocul Immunol Inflamm. 2023 Aug;31(6):1240-1244. (PMID: 36228041)
Ocul Immunol Inflamm. 2021 May 19;29(4):730-733. (PMID: 34187278)
QJM. 2023 Feb 24;116(2):127-129. (PMID: 36355470)
Retina. 2010 Jul-Aug;30(7):1046-50. (PMID: 20559157)
Rev Med Virol. 2022 Jul;32(4):e2313. (PMID: 34755408)
Indian J Ophthalmol. 2021 Oct;69(10):2862-2864. (PMID: 34571652)
Korean J Ophthalmol. 2022 Oct;36(5):471-473. (PMID: 35989067)
Cureus. 2023 Feb 26;15(2):e35499. (PMID: 37007380)
Ocul Immunol Inflamm. 2023 Aug;31(6):1222-1225. (PMID: 35914286)
J Ophthalmol. 2014;2014:403042. (PMID: 24757559)
Ocul Immunol Inflamm. 2023 Aug;31(6):1273-1278. (PMID: 36737061)
Retin Cases Brief Rep. 2022 Jan 1;16(1):16-19. (PMID: 31990820)
Nature. 2020 Oct;586(7830):516-527. (PMID: 32967006)
Vaccines (Basel). 2022 Jun 09;10(6):. (PMID: 35746527)
J Ophthalmic Inflamm Infect. 2021 Dec 18;11(1):45. (PMID: 34921620)
Vaccines (Basel). 2021 Nov 17;9(11):. (PMID: 34835280)
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1234-1237. (PMID: 34662254)
Eye (Lond). 2022 Mar;36(3):644-645. (PMID: 34158652)
Ocul Immunol Inflamm. 2019;27(4):528-530. (PMID: 29370556)
Am J Ophthalmol. 2004 Mar;137(3):538-50. (PMID: 15013878)
Int Ophthalmol. 2023 Aug;43(8):2971-2981. (PMID: 37000311)
Eur J Epidemiol. 2020 Jan;35(1):49-60. (PMID: 31720912)
Vaccines (Basel). 2022 Dec 14;10(12):. (PMID: 36560553)
Nature. 2021 Apr;592(7853):283-289. (PMID: 33524990)
Am J Ophthalmol Case Rep. 2021 Dec;24:101200. (PMID: 34485760)
J Fr Ophtalmol. 2023 Jan;46(1):72-82. (PMID: 36496293)
Middle East Afr J Ophthalmol. 2009 Oct;16(4):202-18. (PMID: 20404987)
Ocul Immunol Inflamm. 2023 Apr;31(3):660-664. (PMID: 35226580)
Case Rep Ophthalmol. 2022 Jul 18;13(2):570-577. (PMID: 36160480)
Clin Ophthalmol. 2022 Mar 31;16:987-992. (PMID: 35392428)
Ocul Immunol Inflamm. 2022 Jul;30(5):1240-1243. (PMID: 35201960)
Ocul Immunol Inflamm. 2022 Jul;30(5):1222-1227. (PMID: 35050826)
JAMA Ophthalmol. 2021 Oct 1;139(10):1131-1135. (PMID: 34473209)
Retina. 2021 Dec 1;41(12):2462-2471. (PMID: 34369440)
BMJ Case Rep. 2022 Jun 24;15(6):. (PMID: 35750434)
Eur J Ophthalmol. 2023 May;33(3):NP118-NP121. (PMID: 35306917)
Vaccines (Basel). 2022 Jun 13;10(6):. (PMID: 35746549)
Am J Ophthalmol Case Rep. 2022 Jun;26:101532. (PMID: 35434421)
Taiwan J Ophthalmol. 2022 Aug 01;12(4):465-471. (PMID: 36660122)
فهرسة مساهمة: Keywords: COVID-19; Chorioretinopathy; Multiple evanescent white dot syndrome; Ophthalmology; SARS-CoV-2
تواريخ الأحداث: Date Created: 20240423 Date Completed: 20240423 Latest Revision: 20240514
رمز التحديث: 20240515
مُعرف محوري في PubMed: PMC11039548
DOI: 10.1007/s10792-024-03119-4
PMID: 38652153
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-2630
DOI:10.1007/s10792-024-03119-4